German biotechnology company BioNTech SE (Nasdaq:BNTX) reported on Monday total revenue of EUR3.2bn for the second quarter of 2022, down from EUR5.3bn in the same period a year ago.
In the first six months of the year, total revenue grew to EUR9.6bn from EUR7.4bn a year earlier.
Net profit for the second quarter amounted to EUR1.7bn, compared with EUR2.8bn in the second quarter last year, with the first-half figures showing an increase to EUR5.4bn from EUR3.9bn in the first six months of 2021.
The company fell short of sales and earnings expectations in the second quarter after the European Commission renegotiated its COVID-19 vaccine contract. Doses scheduled for delivery in June-August 2022 will now be delivered in September through to the fourth quarter of 2022. This change of delivery schedule did not impact the company's full-year 2022 revenue guidance or the full-year commitment of doses to be delivered to EU member states in 2022.
BioNTech also said that, with its partner Pfizer Inc (NYSE:PFE), it plans to launch a clinical trial this month of a COVID-19 vaccine adapted to the BA.4 and BA.5 variants of Omicron.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT